Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

RVMD

Revolution Medicines, Inc.

Tremor tracks 13 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

    Signing up patientsPhase 3670 patientsMain results: Dec 30, 2028
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    Signing up patientsPhase 3590 patientsMain results: Dec 1, 2027
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

    Signing up patientsPhase 3400 patientsMain results: Mar 2029
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    Signing up patientsPhase 1/2370 patientsMain results: May 2029
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

    Signing up patientsPhase 3430 patientsMain results: Oct 2029
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    Signing up patientsPhase 3500 patientsMain results: May 10, 2029
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    Signing up patientsPhase 1/2616 patientsMain results: Jun 2027
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    Signing up patientsPhase 3900 patientsMain results: Jun 2028
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    Signing up patientsPhase 1/2534 patientsMain results: Dec 2028
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    Signing up patientsPhase 1/21,130 patientsMain results: Sep 30, 2028
  • RVMDRevolution Medicines, Inc.
    0Calm

    Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

    Running, no new patientsPhase 3500 patientsMain results: Jun 2026
  • RVMDRevolution Medicines, Inc.
    0Calm

    Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Signing up patientsPhase 1/2754 patientsMain results: May 31, 2027
  • RVMDRevolution Medicines, Inc.
    0Calm

    Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

    FinishedPhase 247 patientsMain results: Jul 3, 2024

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

110 sales (1 not pre-planned) · 0 purchases

  • Mancini AnthonySee Remarks · Oct 26, 2026Sold 2,310 sharesabout $432 thousand · pre-planned
  • Sandler Alan B.Chief Development Officer · Sep 29, 2026Sold 2,200 sharesabout $442 thousand · pre-planned
  • Sandler Alan B.Chief Development Officer · Sep 29, 2026Sold 1,609 sharesabout $325 thousand · pre-planned
  • Sandler Alan B.Chief Development Officer · Sep 29, 2026Sold 1,000 sharesabout $203 thousand · pre-planned
  • Sandler Alan B.Chief Development Officer · Sep 29, 2026Sold 1,199 sharesabout $244 thousand · pre-planned
  • Sandler Alan B.Chief Development Officer · Sep 29, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • Quarterly reportQuarterly report (10-Q)Nov 4, 2026
  • Shared quarterly resultsNews report (8-K)Nov 4, 2026
  • Other newsNews report (8-K)Oct 13, 2026
  • Signed a major agreementNews report (8-K)Sep 1, 2026
  • Other newsNews report (8-K)Aug 26, 2026

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.
Sold 301 sharesabout $62 thousand · pre-planned
  • Cislini JeffSVP & General Counsel · Sep 25, 2026Sold 765 sharesabout $159 thousand · pre-planned
  • Mancini AnthonySee Remarks · Sep 25, 2026Sold 3,121 sharesabout $626 thousand · pre-planned
  • Mancini AnthonySee Remarks · Sep 24, 2026Sold 587 sharesabout $117 thousand · pre-planned
  • ANDERSON ELIZABETH MBoard member · Sep 22, 2026Sold 910 sharesabout $175 thousand · pre-planned
  • ANDERSON ELIZABETH MBoard member · Sep 22, 2026Sold 4,985 sharesabout $960 thousand · pre-planned
  • ANDERSON ELIZABETH MBoard member · Sep 22, 2026Sold 2,648 sharesabout $512 thousand · pre-planned
  • ANDERSON ELIZABETH MBoard member · Sep 22, 2026Sold 1,500 sharesabout $292 thousand · pre-planned
  • ANDERSON ELIZABETH MBoard member · Sep 22, 2026Sold 100 sharesabout $20 thousand · pre-planned
  • Mancini AnthonySee Remarks · Sep 18, 2026Sold 1,764 sharesabout $347 thousand · pre-planned
  • Sandler Alan B.Chief Development Officer · Sep 16, 2026Sold 5 sharesabout $975 · pre-planned
  • Sandler Alan B.Chief Development Officer · Sep 16, 2026Sold 336 sharesabout $67 thousand · pre-planned
  • Mancini AnthonySee Remarks · Sep 16, 2026Sold 27 sharesabout $5 thousand · pre-planned
  • Mancini AnthonySee Remarks · Sep 16, 2026Sold 1,747 sharesabout $348 thousand · pre-planned
  • Kelsey Stephen MichaelSee Remarks · Sep 16, 2026Sold 85 sharesabout $17 thousand · pre-planned
  • Kelsey Stephen MichaelSee Remarks · Sep 16, 2026Sold 5,484 sharesabout $1.1 million · pre-planned
  • Horn Margaret AChief Operating Officer · Sep 16, 2026Sold 76 sharesabout $15 thousand · pre-planned
  • Horn Margaret AChief Operating Officer · Sep 16, 2026Sold 4,891 sharesabout $975 thousand · pre-planned
  • GOLDSMITH MARK ASee Remarks · Sep 16, 2026Sold 213 sharesabout $42 thousand · pre-planned
  • GOLDSMITH MARK ASee Remarks · Sep 16, 2026Sold 13,775 sharesabout $2.7 million · pre-planned
  • Cislini JeffSVP & General Counsel · Sep 16, 2026Sold 52 sharesabout $10 thousand · pre-planned
  • Cislini JeffSVP & General Counsel · Sep 16, 2026Sold 3,314 sharesabout $660 thousand · pre-planned
  • Anders JackChief Financial Officer · Sep 16, 2026Sold 61 sharesabout $12 thousand · pre-planned
  • Anders JackChief Financial Officer · Sep 16, 2026Sold 3,992 sharesabout $796 thousand · pre-planned
  • Kelsey Stephen MichaelSee Remarks · Sep 11, 2026Sold 800 sharesabout $159 thousand · pre-planned

    • Showing the 30 most recent.

    Quarterly reportQuarterly report (10-Q)
    Aug 5, 2026
  • Shared quarterly resultsNews report (8-K)Aug 5, 2026
  • An executive or board member joined or leftNews report (8-K)Jun 22, 2026